Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 4

Sponsor Class

OTHER 5INDUSTRY 4OTHER_GOV 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Neoplasms 6Stomach Neoplasms 5Melanoma 5Carcinoma, Hepatocellular 5Breast Neoplasms 5Triple Negative Breast Neoplasms 4Solid Tumor 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Small Cell Lung Carcinoma 3Sarcoma 3Nasopharyngeal Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Liver Neoplasms 2Liposarcoma 2Esophageal Squamous Cell Carcinoma 2Uterine Cervical Neoplasms 1Solid Tumor, Adult 1Solid Cancer 1Recurrence 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Nasopharyngeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1

Interventions

pembrolizumab 51Nivolumab 27Gemcitabine 23atezolizumab 19Cisplatin 18Carboplatin 18enfortumab vedotin 15avelumab 15Mitomycin 14Docetaxel 8Ipilimumab 7Paclitaxel 6Injections 5Cyclophosphamide 5vinflunine 4toripalimab 4tislelizumab 4lenvatinib 4fludarabine 4epacadostat 4Pemetrexed 4130-nm albumin-bound paclitaxel 4sacituzumab govitecan 3disitamab vedotin 3Rogaratinib 3Interleukin-2 3ALT-803 3vofatamab 2valrubicin 2rucaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Transitional Cell × toripalimab × Clear all
NCT07314723 2026-01-02

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06823427 2025-03-21

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 2 Recruiting
60 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT06592326 2024-09-19

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 3 Recruiting
460 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT05302284 2023-12-18

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

RemeGen Co., Ltd.

Phase 3 Recruiting
452 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡